Current Assets
Cash & Equivalents
Kailera Therapeutics Cash & Equivalents decreased by 30.2% to $111.83M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
Peer comparison
A universal metric for assessing a company's immediate financial health.
Metric ID:
cash_and_equivalentsHistorical Data
3 periods
| Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $101.78M | $160.27M | $111.83M |
| QoQ Change | — | +57.5% | -30.2% |
| YoY Change | — | — | +9.9% |
Range$101.78M – $160.27M
Avg YoY Growth+9.9%
Median YoY Growth+9.9%
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's cash & equivalents?
- Kailera Therapeutics (KLRA) reported cash & equivalents of $111.83M in Q1 2026.
- What does cash & equivalents mean?
- Cash and highly liquid assets that can be converted to cash within 90 days.